Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Current Assets (2024 - 2025)

Kairos Pharma's Current Assets history spans 2 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Current Assets rose 29.22% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $5.4 million, up 29.22%, while the annual FY2025 figure was $5.4 million, 29.22% up from the prior year.
  • Current Assets reached $5.4 million in Q4 2025 per KAPA's latest filing, up from $4.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $6.0 million in Q1 2025 to a low of $4.2 million in Q4 2024.